Strategic Investment Myra Vision has recently secured $25M in Series B funding to accelerate product development, scale manufacturing, and support first-in-human studies for the Calibreye System, signaling robust investor confidence and potential for rapid growth opportunities.

Glaucoma Focus The Calibreye System targets intraocular pressure reduction for moderate to advanced glaucoma, presenting a compelling value proposition to ophthalmology clinics, surgical centers, and specialty eyewear practices looking to expand glaucoma treatment offerings.

Manufacturing Scale With funding aimed at scaling manufacturing capabilities, there is potential to partner on contract manufacturing, supply chain optimization, and volume-driven procurement for ophthalmic devices and related disposables.

Early Commercial Readiness Recent Series A and B financings indicate a maturing product and roadmap, suggesting readiness to engage with early adopters, clinical sites, and distributors for pilot programs, training, and accelerated rollout.

Strategic Partnership As a Shifamed LLC portfolio company, Myra Vision may be open to collaboration on co-development, licensing, or rotational sales partnerships with ophthalmology device distributors and medical technology firms seeking complementary glaucoma solutions.